BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the SG Cowen & Co. 6th Annual Global Health Care Conference in Barcelona, Spain on Thursday, November 10, 2005, at 9:45 a.m. Central European Time (3:45 a.m. ET).

Interested parties may access a live audio webcast of the presentation via the investor section of the BioMarin website, www.BMRN.com. A replay of the presentation will be archived on the site for at least one week following the presentation.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), and Orapred(R) (prednisolone sodium phosphate oral solution) for inflammatory conditions. Investigational product candidates include Phenoptin(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU). For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Orapred(R) is a registered trademark of Medicis Pediatrics, Inc. and is used under license.

   Contacts:

   Investors                             Media
   Joshua A. Grass                       Susan Ferris
   BioMarin Pharmaceutical Inc.          BioMarin Pharmaceutical Inc.
   (415) 506-6777                        (415) 506-6701

SOURCE: BioMarin Pharmaceutical Inc.